Please login to the form below

Not currently logged in
Email:
Password:

Exviera

This page shows the latest Exviera news and features for those working in and with pharma, biotech and healthcare.

Gilead’s hepatitis C sales start to slide – the question is how quickly?

Gilead’s hepatitis C sales start to slide – the question is how quickly?

UK. New entrants such as AbbVie's Viekirax (paritaprevir, ombitasvir and ritonavir) and Exviera (dasabuvir) and Merck &Co's Zepatier (elbasvir/grazoprevir) have also played a role, although Gilead maintains that

Latest news

More from news
Approximately 2 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • AbbVie: New firm, new thinking AbbVie: New firm, new thinking

    However, AbbVie is set to make an impact in 2015 with the launch of its own interferon-free regimen for hepatitis C, a combination of Viekirax (ombitasvir/paritaprevir/ritonavir) and Exviera

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics